Windward Bio

Business financing
#Asthma #Financing #Immunology #Monoclonal antibodies #Windward Bio

Windward Bio launches with $200 million

Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch.   OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal… Read More

#Business & Investment #News #Start-up Zone